ストックスクリーナーアプリを入手
19.85
2.90%
0.56
プレマーケット:
19.30
-0.55
-2.77%
前日終値:
$19.29
開ける：
$19.45
24時間の取引高:
84,224
Relative Volume:
0.72
時価総額：
$510.65M
収益：
$26.00M
当期純損益:
$-219.71M
株価収益率:
-0.3986
EPS:
-49.8
ネットキャッシュフロー:
$-51.37M
1週間 パフォーマンス:
+10.16%
1か月 パフォーマンス:
+4.36%
6か月 パフォーマンス:
+22.83%
1年 パフォーマンス:
-13.28%
1日の値動き範囲:
$19.15
$20.00
1週間の範囲:
$18.09
$20.12
52週間の値動き範囲:
$11.66
$41.87
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
名前
Cartesian Therapeutics Inc
セクター
電話
301-348-8698
住所
7495 NEW HORIZON WAY, FREDERICK
RNAC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
19.85 | 510.65M | 26.00M | -219.71M | -51.37M | -49.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-19 | 開始されました | BTIG Research | Buy |
| 2024-08-06 | 開始されました | TD Cowen | Buy |
| 2024-07-02 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-06-04 | 開始されました | Oppenheimer | Outperform |
| 2024-05-24 | 開始されました | Mizuho | Buy |
| 2024-04-23 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-04-23 | 開始されました | Leerink Partners | Outperform |
| 2023-08-18 | ダウングレード | SVB Securities | Outperform → Market Perform |
| 2022-06-14 | 繰り返されました | Needham | Buy |
| 2022-06-06 | 開始されました | SVB Leerink | Outperform |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-01-26 | アップグレード | Mizuho | Neutral → Buy |
| 2020-10-01 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-10-01 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2020-06-12 | ダウングレード | Stifel | Buy → Hold |
| 2020-04-28 | 開始されました | H.C. Wainwright | Buy |
| 2020-01-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-01-21 | 開始されました | William Blair | Outperform |
| 2018-06-27 | 開始されました | Janney | Buy |
| 2017-03-30 | 繰り返されました | UBS | Buy |
すべてを表示
Cartesian Therapeutics Inc (RNAC) 最新ニュース
Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Target Price at $42.86 - Defense World
Cartesian Therapeutics: Need To Wait For More Data For Its Novel mRNA Therapies - Seeking Alpha
Cartesian Therapeutics director Timothy Springer acquires $366k in stock By Investing.com - Investing.com Nigeria
Cartesian Therapeutics director Timothy Springer acquires $366k in stock - Investing.com India
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $42.86 Consensus PT from Brokerages - MarketBeat
Cartesian Therapeutics’ (RNAC) Buy Rating Reaffirmed at Needham & Company LLC - Defense World
Needham & Company LLC Reiterates "Buy" Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat
Cartesian Therapeutics Sets 2025 Strategy for Descartes-08 - TipRanks
Cartesian Therapeutics Highlights Progress and 2025 - GlobeNewswire
Cartesian's Descartes-08 Shows Strong Phase 2b Results in Myasthenia Gravis, Phase 3 Trial Planned - StockTitan
Myasthenia Gravis Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen R&D, Immunovant - The Globe and Mail
Myasthenia Gravis Market Poised for Significant Growth from - openPR
Cartesian Therapeutics chief scientific officer sells $42,782 in stock By Investing.com - Investing.com Australia
Geode Capital Management LLC Raises Stock Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian therapeutics COO Emily English sells $30,149 in stock By Investing.com - Investing.com Nigeria
Cartesian Therapeutics CFO sells shares worth $134,035 By Investing.com - Investing.com South Africa
Carsten Brunn sells $289,764 in Cartesian Therapeutics shares By Investing.com - Investing.com South Africa
Cartesian Therapeutics CTO Metin Kurtoglu sells $81,790 in stock By Investing.com - Investing.com Canada
Cartesian Therapeutics CMO Milos Miljkovic sells $31,541 in stock By Investing.com - Investing.com Nigeria
Cartesian Therapeutics CFO sells shares worth $134,035 - Investing.com India
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) CTO Sells $40,412.24 in Stock - MarketBeat
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) CTO Metin Kurtoglu Sells 2,458 Shares - MarketBeat
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Insider Milos Miljkovic Sells 948 Shares - MarketBeat
Cartesian Therapeutics chief scientific officer sells $42,782 in stock - Investing.com
Cartesian Therapeutics CTO Metin Kurtoglu sells $81,790 in stock - Investing.com
Carsten Brunn sells $289,764 in Cartesian Therapeutics shares - Investing.com
Cartesian Therapeutics Announces New Employment Inducement Grants - The Manila Times
Cartesian Therapeutics Awards Stock Options to New Employees in Retention Move - StockTitan
Barclays PLC Purchases 7,849 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Risks Still Elevated At These Prices As Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Dive 33% - Simply Wall St
Critical Review: Cartesian Therapeutics (RNAC) vs. The Competition - Defense World
State Street Corp Has $2.54 Million Stock Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics (NASDAQ:RNAC) Trading 7.2% HigherStill a Buy? - MarketBeat
Cartesian Therapeutics ATM - Leerink Partners
Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) PT at $42.86 - Defense World
Cartesian therapeutics director Timothy Springer buys $965k in stock By Investing.com - Investing.com Nigeria
Cartesian therapeutics director Timothy Springer buys $965k in stock - Investing.com
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
BNP Paribas Financial Markets Has $27,000 Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics initiated with a Buy at BTIG - Yahoo Finance
BTIG Research Initiates Coverage on Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat
BTIG initiates Buy rating on Cartesian Therapeutics stock highlighting mRNA CAR-T potential - Investing.com
Cartesian Therapeutics Awards Key Talent with mRNA Cell Therapy Stock Options in Strategic Growth Move - StockTitan
Fmr LLC Boosts Stock Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Fmr LLC Has $45.97 Million Stake in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - MarketBeat
HC Wainwright Reiterates Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics Inc (RNAC) 財務データ
収益
当期純利益
現金流量
EPS
Cartesian Therapeutics Inc (RNAC) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| SPRINGER TIMOTHY A | Director |
Jan 14 '25 |
Buy |
18.00 |
4,022 |
72,396 |
8,531,462 |
| Jewell Christopher M | Chief Scientific Officer |
Jan 10 '25 |
Option Exercise |
3.23 |
9,000 |
29,070 |
62,490 |
| Kurtoglu Metin | Chief Technology Officer |
Jan 06 '25 |
Sale |
16.83 |
2,458 |
41,374 |
62,258 |
| Kurtoglu Metin | Chief Technology Officer |
Jan 03 '25 |
Sale |
16.72 |
2,417 |
40,417 |
64,716 |
| Miljkovic Milos | Chief Medical Officer |
Jan 06 '25 |
Sale |
16.83 |
948 |
15,957 |
35,393 |
| Miljkovic Milos | Chief Medical Officer |
Jan 03 '25 |
Sale |
16.72 |
932 |
15,585 |
36,341 |
| Jewell Christopher M | Chief Scientific Officer |
Jan 06 '25 |
Sale |
16.83 |
1,286 |
21,646 |
53,490 |
| Jewell Christopher M | Chief Scientific Officer |
Jan 03 '25 |
Sale |
16.72 |
1,264 |
21,136 |
54,776 |
| English Emily | Chief Operations Officer |
Jan 06 '25 |
Sale |
16.83 |
906 |
15,250 |
40,226 |
| English Emily | Chief Operations Officer |
Jan 03 '25 |
Sale |
16.72 |
891 |
14,899 |
41,132 |
4.81%
大文字化:
|
ボリューム (24 時間):